These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

688 related items for PubMed ID: 9361038

  • 21. BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy.
    Santarosa M, Dolcetti R, Magri MD, Crivellari D, Tibiletti MG, Gallo A, Tumolo S, Della Puppa L, Furlan D, Boiocchi M, Viel A.
    Int J Cancer; 1999 Sep 24; 83(1):5-9. PubMed ID: 10449599
    [Abstract] [Full Text] [Related]

  • 22. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
    Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung N, Warner E, Rosen B, Friedman J, Brunet JS, Narod SA.
    Am J Hum Genet; 2000 Apr 24; 66(4):1259-72. PubMed ID: 10739756
    [Abstract] [Full Text] [Related]

  • 23. Exclusion of large deletions and other rearrangements in BRCA1 and BRCA2 in Finnish breast and ovarian cancer families.
    Lahti-Domenici J, Rapakko K, Pääkkönen K, Allinen M, Nevanlinna H, Kujala M, Huusko P, Winqvist R.
    Cancer Genet Cytogenet; 2001 Sep 24; 129(2):120-3. PubMed ID: 11566341
    [Abstract] [Full Text] [Related]

  • 24. High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families.
    Ganguly T, Dhulipala R, Godmilow L, Ganguly A.
    Hum Genet; 1998 May 24; 102(5):549-56. PubMed ID: 9654203
    [Abstract] [Full Text] [Related]

  • 25. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
    Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DE, Provencher D, Ghadirian P, Narod SA.
    Am J Hum Genet; 1998 Nov 24; 63(5):1341-51. PubMed ID: 9792861
    [Abstract] [Full Text] [Related]

  • 26. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
    de la Hoya M, Osorio A, Godino J, Sulleiro S, Tosar A, Perez-Segura P, Fernandez C, Rodríguez R, Díaz-Rubio E, Benítez J, Devilee P, Caldés T.
    Int J Cancer; 2002 Feb 01; 97(4):466-71. PubMed ID: 11802208
    [Abstract] [Full Text] [Related]

  • 27. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
    Martin AM, Blackwood MA, Antin-Ozerkis D, Shih HA, Calzone K, Colligon TA, Seal S, Collins N, Stratton MR, Weber BL, Nathanson KL.
    J Clin Oncol; 2001 Apr 15; 19(8):2247-53. PubMed ID: 11304778
    [Abstract] [Full Text] [Related]

  • 28. Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer.
    Chang-Claude J, Becher H, Caligo M, Eccles D, Evans G, Haites N, Hodgson S, Møller P, Weber BH, Stoppa-Lyonnet D.
    Dis Markers; 1999 Oct 15; 15(1-3):53-65. PubMed ID: 10595253
    [Abstract] [Full Text] [Related]

  • 29. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
    Stadler ZK, Saloustros E, Hansen NA, Schluger AE, Kauff ND, Offit K, Robson ME.
    Breast Cancer Res Treat; 2010 Sep 15; 123(2):581-5. PubMed ID: 20221693
    [Abstract] [Full Text] [Related]

  • 30. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
    Durocher F, Labrie Y, Soucy P, Sinilnikova O, Labuda D, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Ouellette G, Pichette R, Plante M, Tavtigian SV, Simard J.
    BMC Cancer; 2006 Sep 29; 6():230. PubMed ID: 17010193
    [Abstract] [Full Text] [Related]

  • 31. Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing.
    Unger MA, Nathanson KL, Calzone K, Antin-Ozerkis D, Shih HA, Martin AM, Lenoir GM, Mazoyer S, Weber BL.
    Am J Hum Genet; 2000 Oct 29; 67(4):841-50. PubMed ID: 10978226
    [Abstract] [Full Text] [Related]

  • 32. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
    Górski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, Pluzańska A, Bebenek M, Fischer-Maliszewska L, Grzybowska E, Narod SA, Lubiński J.
    Am J Hum Genet; 2000 Jun 29; 66(6):1963-8. PubMed ID: 10788334
    [Abstract] [Full Text] [Related]

  • 33. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2.
    Schubert EL, Lee MK, Mefford HC, Argonza RH, Morrow JE, Hull J, Dann JL, King MC.
    Am J Hum Genet; 1997 May 29; 60(5):1031-40. PubMed ID: 9150150
    [Abstract] [Full Text] [Related]

  • 34. Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
    De Benedetti VM, Radice P, Pasini B, Stagi L, Pensotti V, Mondini P, Manoukian S, Conti A, Spatti G, Rilke F, Pierotti MA.
    Hum Mutat; 1998 May 29; 12(3):215. PubMed ID: 10660329
    [Abstract] [Full Text] [Related]

  • 35. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL, Smith AM, Dávila MR, Sigurdson AJ, Giusti RM, Pineda MA, Doody MM, Tucker MA, Greene MH, Zhang J, Struewing JP.
    Hum Mutat; 2003 Aug 29; 22(2):121-8. PubMed ID: 12872252
    [Abstract] [Full Text] [Related]

  • 36. Genetic testing for breast cancer susceptibility: frequency of BRCA1 and BRCA2 mutations.
    Ganguly A, Leahy K, Marshall AM, Dhulipala R, Godmilow L, Ganguly T.
    Genet Test; 1997 Aug 29; 1(2):85-90. PubMed ID: 10464631
    [Abstract] [Full Text] [Related]

  • 37. Evidence of founder mutations in Finnish BRCA1 and BRCA2 families.
    Huusko P, Pääkkönen K, Launonen V, Pöyhönen M, Blanco G, Kauppila A, Puistola U, Kiviniemi H, Kujala M, Leisti J, Winqvist R.
    Am J Hum Genet; 1998 Jun 29; 62(6):1544-8. PubMed ID: 9585608
    [No Abstract] [Full Text] [Related]

  • 38. Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families.
    Kumar BV, Lakhotia S, Ankathil R, Madhavan J, Jayaprakash PG, Nair MK, Somasundaram K.
    Cancer Biol Ther; 2002 Jun 29; 1(1):18-21. PubMed ID: 12170759
    [Abstract] [Full Text] [Related]

  • 39. Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes?
    Serova OM, Mazoyer S, Puget N, Dubois V, Tonin P, Shugart YY, Goldgar D, Narod SA, Lynch HT, Lenoir GM.
    Am J Hum Genet; 1997 Mar 29; 60(3):486-95. PubMed ID: 9042907
    [Abstract] [Full Text] [Related]

  • 40. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
    Patmasiriwat P, Bhothisuwan K, Sinilnikova OM, Chopin S, Methakijvaroon S, Badzioch M, Padungsutt P, Vattanaviboon P, Vattanasapt V, Szabo C, Saunders GF, Goldgar D, Lenoir GM.
    Hum Mutat; 2002 Sep 29; 20(3):230. PubMed ID: 12203997
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.